Naturewise Biotech & Medicals (ROCO:4732) Other Current Payables: NT$32.9 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4732 Naturewise Biotech & Medicals Corp ROCO:4732
58 GF Score
Price NT$16.50
GF Value NT$22.06
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Naturewise Biotech & Medicals Other Current Payables?

Naturewise Biotech & Medicals ROCO:4732 -0.30% 58 Other Current Payables is NT$32.9 Mil as of Dec. 2025. GuruFocus rates ROCO:4732 with a GF Score™ of 58/100 and a GF Value™ of NT$22.06 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Naturewise Biotech & Medicals's Other Current Payables for the quarter that ended in Dec. 2025 was NT$32.9 Mil.

Naturewise Biotech & Medicals's quarterly Other Current Payables increased from Dec. 2024 (NT$18.8 Mil) to Jun. 2025 (NT$19.9 Mil) and increased from Jun. 2025 (NT$19.9 Mil) to Dec. 2025 (NT$32.9 Mil).

Naturewise Biotech & Medicals's annual Other Current Payables declined from Dec. 2023 (NT$19.6 Mil) to Dec. 2024 (NT$18.8 Mil) but then increased from Dec. 2024 (NT$18.8 Mil) to Dec. 2025 (NT$32.9 Mil).

Naturewise Biotech & Medicals Other Current Payables Related Terms

Naturewise Biotech & Medicals Other Current Payables Historical Data

* Premium members only.

The historical data trend for Naturewise Biotech & Medicals's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Naturewise Biotech & Medicals Other Current Payables Chart

Naturewise Biotech & Medicals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Payables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 32.40 25.89 19.61 18.83 32.91

Naturewise Biotech & Medicals Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.61 30.81 18.83 19.85 32.91
ROCO:4732
58GF Score
Naturewise Biotech & Medicals Corp ROCO:4732
Other Current Payables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Naturewise Biotech & Medicals Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of NT$32.9 Mil mean?
Naturewise Biotech & Medicals (ROCO:4732) has a Other Current Payables of NT$32.9 Mil as of Dec. 2025. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Naturewise Biotech & Medicals and its competitors.
Is Naturewise Biotech & Medicals' Other Current Payables too high?
Naturewise Biotech & Medicals' current Other Current Payables is NT$32.9 Mil. Overall, Naturewise Biotech & Medicals has a GF Score™ of 58/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Naturewise Biotech & Medicals' Other Current Payables compare to VRTX and REGN?
Naturewise Biotech & Medicals' Other Current Payables of NT$32.9 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Biotechnology company?
A good Other Current Payables depends on the Biotechnology industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Naturewise Biotech & Medicals and its competitors. Naturewise Biotech & Medicals's current Other Current Payables is NT$32.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Naturewise Biotech & Medicals stock overvalued right now?
Based on GuruFocus' analysis, Naturewise Biotech & Medicals (ROCO:4732) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$22.06, compared to a current price of NT$16.50 — trading 25.2% below its estimated fair value. The current Other Current Payables is NT$32.9 Mil. Naturewise Biotech & Medicals' overall GF Score™ is 58/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For Naturewise Biotech & Medicals (ROCO:4732), the current Other Current Payables is NT$32.9 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Naturewise Biotech & Medicals (ROCO:4732) Overvalued in 2026?

Based on GuruFocus' analysis, Naturewise Biotech & Medicals stock appears to be undervalued. The current stock price of NT$16.50 is trading 25.2% below its estimated GF Value™ of NT$22.06. GuruFocus considers Naturewise Biotech & Medicals to be Modestly Undervalued.

Key valuation signals for ROCO:4732:

  • Other Current Payables: NT$32.9 Mil
  • GF Value™: NT$22.06 vs. price of NT$16.50 (25.2% below fair value)
  • GF Score™: 58/100 with 3 warning signs

No single metric tells the full story. See the ROCO:4732 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Naturewise Biotech & Medicals Business Description

Address No. 36, Bade Road, 6th Floor, Section 3, Songshan District, Taipei, TWN, 105
Naturewise Biotech & Medicals Corp is a Taiwan-based drug development company that focuses on botanical drug and small molecule therapies. Its products include NBM-BMX Oral Softgel Capsule, Lipocol Forte Capsule, and PPLs Taiwan Green Propolis.
58GF Score

Get the complete analysis for ROCO:4732

Other Current Payables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$16.50
Price
NT$22.06
GF Value